REDWOOD CITY, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the issuance of its fourth broad U.S. patent relating to antibodies that target the RSPO-LGR cancer stem cell pathway. The new patent, U.S. Patent No. 8,628,774, covers certain methods of treating cancer with antibodies that bind human leucine-rich repeat-containing G protein-coupled receptor (LGR) proteins and either disrupt the binding of such proteins to their ligands, the R-spondin (RSPO) proteins, or disrupt RSPO activation of LGR signaling. RSPO-LGR pathway patents previously granted to OncoMed include U.S. Patent Nos. 8,158,757, 8,158,758 and 8,540,989.
OncoMed Pharmaceuticals Granted Fourth RSPO-LGR Pathway Patent In U.S.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.